Summary
The provided AI statements concern patent portfolio and market-entry timing rather than FDA-approved XARELTO prescribing information content (indications, dosing, contraindications, boxed warnings, safety, interactions, or administration). As a result, no on-label prescribing alignment can be established from the supplied label excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Xarelto (rivaroxaban) has multiple patent families.
No support or evaluation possible from the provided FDA prescribing information excerpts (boxed warning and sections 2.3/2.4/5.1/5.3/6.2 only).
The “expiration date” for Xarelto depends on which patent(s) are meant (drug substance, formulations, dosing/regimen, or specific process patents).
Not addressed in the provided prescribing information excerpts.
Generic or biosimilar entry timing is usually tied to the last-to-expire patent covering the product.
Not addressed in the provided prescribing information excerpts.
In the U.S., generic or biosimilar entry timing may also be affected by additional regulatory exclusivities and litigation stay effects.
Not addressed in the provided prescribing information excerpts.
Xarelto’s patent portfolio typically includes separate patents for the active ingredient (and related chemical/process claims), specific tablet formulations/excipients, manufacturing steps, and additional improvements patented later.
Not addressed in the provided prescribing information excerpts.
Each patent family can expire on a different date.
Not addressed in the provided prescribing information excerpts.
Market entry timing is governed by the last blocking rights.
Not addressed in the provided prescribing information excerpts.
Patent expiration dates are only part of the entry picture.
Not addressed in the provided prescribing information excerpts.
Patent litigation and regulatory exclusivity can also delay or permit entry of generic drugs for Xarelto.
Not addressed in the provided prescribing information excerpts.
Contradictions
Important Omissions
If the goal is medication use per label, the AI response does not provide any FDA-label-aligned prescribing content (indications, dosing/administration, contraindications, boxed warning details, warnings/precautions, monitoring, or administration timing around neuraxial anesthesia).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The statements provided do not include dosing, contraindications, or safety instructions; therefore direct patient harm from incorrect dosing guidance cannot be assessed from the provided text. However, absence of label-relevant prescribing information represents a failure to align with the requested FDA label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
The provided AI statements are about patent families and generic entry timing, which are not supported by (or addressed in) the provided FDA prescribing information excerpts.
Suggested Improvement
Provide an FDA-label-aligned response focusing on XARELTO prescribing information topics (boxed warning, dosing/discontinuation guidance around procedures/neuraxial anesthesia, contraindications, precautions, and monitoring) and cite relevant label sections.